Edesa Biotech (EDSA) vs Telomir Pharmaceuticals (TELO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Edesa Biotech (EDSA) has outperformed Telomir Pharmaceuticals (TELO) over the past year, gaining 17.6% versus a loss of 71.6%. Edesa Biotech is the larger company by market cap ($27.0 million vs $26.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EDSA | TELO |
|---|---|---|
| Share price | $2.00 | $0.364 |
| Market cap | $27.02M | $26.82M |
| 1-day change | -8.05% | -17.24% |
| YTD return | +40.85% | -72.63% |
| 1-year return | +17.65% | -71.56% |
| 5-year return | -95.63% | — |
| EPS (TTM) | $-1.72 | $-0.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-7.19M | $-10.41M |
| 52-week high | $20.32 | $1.58 |
| 52-week low | $0.72 | $0.353 |
| Distance from 52-week high | -90.16% | -76.96% |
| Analyst consensus | none | none |
| Avg. price target upside | +716.50% | +998.90% |
| Average volume | 1.45M | 126.14K |
| Shares outstanding | 13.51M | 73.68M |
| Employees | 17 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EDSA has outperformed TELO by 89.2 percentage points over the past year.
About Edesa Biotech
EDSA stock →Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
About Telomir Pharmaceuticals
TELO stock →Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria.
Health Care · Biotechnology: Pharmaceutical Preparations
EDSA vs TELO FAQ
Which is bigger, Edesa Biotech or Telomir Pharmaceuticals?
Edesa Biotech (EDSA) is larger, with a market capitalization of $27.02M compared with $26.82M for Telomir Pharmaceuticals (TELO).
Which stock has performed better over the past year, EDSA or TELO?
EDSA returned +17.65% over the past 12 months, compared with -71.56% for TELO (price return, excluding dividends). Past performance does not predict future results.
Are Edesa Biotech and Telomir Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.